IR
Live price temporarily unavailable.
Price history
Opus Genetics (IRD) is a Health Care company in the Russell 2000. Latest news and coverage below.
Opus Genetics revenue & net income history (FY2016–FY2025)
RevenueNet income
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | — | $3.00M | $0 | $589.0K | $39.9M | $19.0M | $11.0M | $14.2M |
| Growth (year over year) | — | — | — | — | −100.0% | — | +6665.7% | −52.2% | −42.3% | +29.1% |
| Operating income | −$16.4M | −$17.4M | −$20.5M | −$4.19M | −$20.0M | −$22.7M | $18.2M | −$10.6M | −$62.1M | −$38.6M |
| Operating margin | — | — | — | −139.8% | — | −3854.8% | 45.7% | −55.5% | −564.7% | −271.9% |
| Net income | −$9.31M | −$25.3M | −$14.4M | −$6.17M | −$24.6M | −$56.7M | $17.9M | −$9.99M | −$57.5M | −$49.6M |
| Net margin | — | — | — | −205.6% | — | −9625.3% | 44.9% | −52.4% | −523.4% | −349.3% |
| EPS (diluted) | −$61.92 | −$132.48 | −$5.25 | −$2.17 | −$5.28 | −$3.82 | $0.87 | −$0.46 | −$2.15 | −$0.80 |
| Balance sheet | ||||||||||
| Cash and equivalents | $11.6M | $8.90M | $8.74M | $1.54M | $16.4M | $24.5M | $42.6M | $50.5M | $30.3M | $45.1M |
| Total assets | $21.0M | $28.3M | $16.0M | $1.78M | $17.7M | $26.1M | $49.0M | $53.9M | $36.9M | $50.2M |
| Total liabilities | $3.99M | $11.5M | $5.48M | $9.34M | $31.1M | $3.85M | $2.75M | $4.04M | $11.3M | $34.9M |
| Long-term debt | — | — | — | — | — | — | — | — | $0 | $1.13M |
| Shareholders' equity | $17.1M | $16.8M | −$1.70M | −$7.56M | −$13.5M | $22.2M | $46.2M | $49.9M | $6.72M | $15.3M |
| Cash flow | ||||||||||
| Operating cash flow | −$13.2M | −$15.4M | −$18.8M | −$3.59M | −$6.80M | −$19.4M | $14.3M | −$1.11M | −$25.6M | −$35.3M |
| Capital expenditure | — | — | — | $25.0K | $0 | — | — | — | — | — |
| Free cash flow | — | — | — | −$3.62M | −$6.80M | — | — | — | — | — |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.87M | $4.30M | $4.37M | $2.88M | $3.08M | $3.87M | $2.16M | $755.0K |
| Growth (year over year) | −67.6% | — | +155.4% | +159.2% | −20.4% | −10.2% | −50.6% | −73.8% |
| Operating income | −$8.01M | −$38.0M | −$9.93M | −$8.91M | −$8.31M | −$11.5M | −$14.4M | −$16.5M |
| Operating margin | −207.1% | −884.0% | −227.2% | −309.0% | −269.9% | −296.3% | −665.9% | −2182.8% |
| Net income | −$7.53M | −$35.1M | −$8.19M | −$7.42M | −$17.5M | −$16.5M | −$65.5M | −$8.10M |
| Net margin | −194.6% | −816.7% | −187.5% | −257.5% | −566.9% | −427.5% | −3038.2% | −1072.6% |
| EPS (diluted) | −$0.29 | −$1.27 | −$0.24 | −$0.12 | −$0.25 | −$0.19 | −$0.75 | −$0.14 |
| Balance sheet | ||||||||
| Cash and equivalents | $36.6M | $30.3M | $41.8M | $32.4M | $30.8M | $45.1M | $60.0M | $88.8M |
| Total assets | $40.4M | $36.9M | $48.2M | $38.7M | $36.1M | $50.2M | $66.8M | $93.0M |
| Total liabilities | $6.09M | $11.3M | $24.3M | $21.2M | $30.2M | $34.9M | $87.9M | $106.0M |
| Long-term debt | — | $0 | — | $1.00M | $1.07M | $1.13M | $1.20M | $35.3M |
| Shareholders' equity | $34.3M | $6.72M | $5.07M | $17.5M | $5.97M | $15.3M | −$45.8M | −$13.0M |
| Cash flow | ||||||||
| Operating cash flow | −$5.13M | −$7.44M | −$8.99M | −$10.3M | −$6.16M | −$9.83M | −$12.7M | −$11.9M |
From Opus Genetics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Opus Genetics
- Headquarters
- Durham, North Carolina From SEC filings, Oct 2026
Recent News (1)
Other Health Care companies to compare with IRD
- IONS Ionis Pharmaceuticals
- IOVA Iovance Biotherapeutics Inc
- IPHA Innate Pharma
- IPSC Century Therapeutics
- IRMD Iradimed Corp
- IRON Disc Medicine Inc
- IRTC Irhythm Holdings Inc
- IRWD Ironwood Pharma Inc Class a